Oncogene-addicted non-small cell lung cancer highlights from ESMO 2025

Dr Herbert Loong joins us in Berlin to share his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Dr Loong reviews data from the following studies: OptiTROP-Lung04: Sacituzumab tirumotecan vs platinum-based chemotherapy in EGFR-mutated NSCLC following progression on EGFR-TKIs: results from the randomised, multi-centre phase 3 study Zhang L, et al. Abstract LBA5, ESMO 2025 SOHO-01: Sevabertinib (BAY 2927088) in advanced HER2-mutant NSCLC Le X, et al. Abstract LBA75, ESMO 2025 Beamion LUNG 1: Zongertinib as 1st line treatment in patients with advanced HER2-mutant NSCLC Popat S, et al. Abstract LBA74, ESMO 2025 LOXO-RAS-20001: Intracranial efficacy of olomorasib, a 2nd generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases Cassier P, et al. Abstract 1846MO, ESMO 2025 FURMO-003: Phase 2 study of firmonertinib in patients with previously treated advanced/mNSCLC with EGFR Exon 20 insertion mutations Liu Y, et al. Abstract 1848MO, ESMO 2025 Watch this short summary video, download the accompanying slides, and see more updates from ESMO 2025 on our website: https://cor2ed.com/n-connect/programm... Want similar videos and slide sets on the latest data on NSCLC? Update From ELCC 2025: Oncogene-addicted NSCLC: Update from ELCC 2025 Update From ASCO 2025: https://cor2ed.com/n-connect/programm... Update From WCLC 2025: Oncogene-addicted NSCLC: Highlights from WCLC 2025 Follow LUNG CONNECT on: X – https://x.com/lung_connect LinkedIn –   / lungconnect   This video is supported by an Independent Education Grant from Bayer. This video was developed by cor2ed.com Published October 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.